Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056238 · ClinicalTrials.gov registry record · Phase 2
Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy
A Phase 2 study of Stroke and Neurologic Diseases, General, sponsored by Bellus Health Inc. - a GSK company.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT00056238 is a Phase 2 study of Stroke and Neurologic Diseases, General that has completed, run by Bellus Health Inc. - a GSK company. The registered enrollment target is 30 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT00056238, a Phase 2 study of Stroke and Neurologic Diseases, General, has completed, sponsored by Bellus Health Inc. - a GSK company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
The main objective of this study is to evaluate the safety, tolerability and pharmacokinetics of Cerebril™ in Cerebral Amyloid Angiopathy (CAA) patients who have had lobar cerebral hemorrhage.
Conditions Studied
Interventions
- DRUG NC-758 (Anti amyloidotic [Aß] agent)
Study Locations (5)
Kentucky
- University of Kentucky - Lexington
Massachusetts
- Massachusetts General Hospital - Boston
New York
- Columbia University - New York
Ohio
- University of Cincinnati - Cincinnati
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00056238
The ClinicalTrials.gov registry entry for NCT00056238 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The listed sponsor is Bellus Health Inc. - a GSK company, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which NC-758 (Anti amyloidotic [Aß] agent) is the first listed.
NCT00056238 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Kentucky, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT00056238 about?
NCT00056238 is a clinical study titled "Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy". The main objective of this study is to evaluate the safety, tolerability and pharmacokinetics of Cerebril™ in Cerebral Amyloid Angiopathy (CAA) patients who have had lobar cerebral hemorrhage.
What is the current status of trial NCT00056238?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2003-02.
What conditions does trial NCT00056238 study?
This clinical trial studies the following conditions: Stroke, Neurologic Diseases, General.
What interventions are being tested in trial NCT00056238?
The interventions under investigation include: NC-758 (Anti amyloidotic [Aß] agent) (DRUG).
Who is sponsoring clinical trial NCT00056238?
This trial is sponsored by Bellus Health Inc. - a GSK company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00056238 being conducted?
This trial has 5 study locations across Kentucky, Massachusetts, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
RECRUITING · Phase 2
-
Balancing Effortful and Errorless Learning in Naming Treatment for Aphasia
RECRUITING · Phase 2
-
Transcranial Magnetic Stimulation + Language Therapy to Treat Mild Aphasia
RECRUITING · Phase 2
-
Novel Wrist Sensor System to Promote Hemiparetic Arm Use in Home Daily Life of Chronic Stroke Survivors
RECRUITING · Phase 2
-
Transcranial Magnetic Stimulation + Language Therapy to Treat Subacute Aphasia
RECRUITING · Phase 2
-
Myofascial Dysfunction in Post Stroke Shoulder Pain
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.